HERCULES, Calif., July 31, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...

HERCULES, Calif. - Bio-Rad Laboratories (NYSE:BIO), Inc. (NYSE: BIO and BIO.B), a $8.49 billion market cap company known for its life science research and clinical diagnostics products, has announced ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced that MicroVal, the international certification organization for the validation ...

HERCULES, Calif., July 07, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ...

Normal Schwartz has been the Chief Executive Officer or CEO, President, and Chairman of Bio-Rad laboratories since 2003. Meet Bio-Rad laboratories chief executive officer or CEO, Norman Schwartz. The ...

Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...

BIO is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of BIO shares has decreased $1.52 since the market last closed. This is a 0.50% ...